CT-011
- Generic Name
- CT-011
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- -
- Unique Ingredient Identifier
- -
- Background
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
- Associated Conditions
- -
- Associated Therapies
- -
PD-1 Alone or With Dendritic Cell/Renal Cell Carcinoma Fusion Cell Vaccine
- Conditions
- Interventions
- First Posted Date
- 2011-09-28
- Last Posted Date
- 2017-02-08
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 11
- Registration Number
- NCT01441765
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Safety, Tolerability and Efficacy Study of the Monoclonal Antibody, CT-011, in Patients With Metastatic Melanoma
- First Posted Date
- 2011-09-16
- Last Posted Date
- 2016-01-21
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 103
- Registration Number
- NCT01435369
- Locations
- 🇺🇸
Moffitt Cancer Center Cutaneous Oncology Department, Tampa, Florida, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Ruttenberg Cancer Clinic - The Mount Sinai Hospital, New York, New York, United States
CT-011 and p53 Genetic Vaccine for Advanced Solid Tumors
- Conditions
- First Posted Date
- 2011-07-01
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- National Cancer Institute (NCI)
- Registration Number
- NCT01386502
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States
Blockade of PD-1 in Conjunction With the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation
- Conditions
- Interventions
- First Posted Date
- 2010-02-11
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Beth Israel Deaconess Medical Center
- Target Recruit Count
- 35
- Registration Number
- NCT01067287
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇮🇱Rambam Medical Center, Haifa, Israel
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Hepatocellular Carcinoma
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2012-10-23
- Lead Sponsor
- CureTech Ltd
- Target Recruit Count
- 2
- Registration Number
- NCT00966251
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
Safety and Tolerability Study of the Monoclonal Antibody CT-011 in Patients With Chronic Hepatitis C Genotype I Infection
- First Posted Date
- 2009-08-20
- Last Posted Date
- 2014-08-29
- Lead Sponsor
- CureTech Ltd
- Target Recruit Count
- 13
- Registration Number
- NCT00962936
- Locations
- 🇮🇱
Hadassah Medical Center, Jerusalem, Israel
Monoclonal Antibody CT-011 in Combination With Rituximab in Patients With Relapsed Follicular Lymphoma
- First Posted Date
- 2009-05-20
- Last Posted Date
- 2016-06-03
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 32
- Registration Number
- NCT00904722
- Locations
- 🇺🇸
University of Texas MD Anderson Cancer Center, Houston, Texas, United States
Study to Evaluate the Safety, Tolerability and Efficacy of FOLFOX + CT-011 Versus FOLFOX Alone
- First Posted Date
- 2009-04-29
- Last Posted Date
- 2015-07-08
- Lead Sponsor
- Medivation, Inc.
- Target Recruit Count
- 171
- Registration Number
- NCT00890305
- Locations
- 🇺🇸
The Cancer Center of Huntsville, PC, Huntsville, Alabama, United States
🇧🇬InterDistrict Dispensary of Oncology Diseases with Stationary, Varna, Bulgaria
🇧🇬InterDistrict Dispensary in Oncology Diseases with Stationary, Shumen, Bulgaria
CT-011 MAb in DLBCL Patients Following ASCT
- Conditions
- Interventions
- First Posted Date
- 2007-09-20
- Last Posted Date
- 2014-09-12
- Lead Sponsor
- CureTech Ltd
- Target Recruit Count
- 72
- Registration Number
- NCT00532259
- Locations
- 🇺🇸
Rush University Medical Center, Chicago, Illinois, United States
🇺🇸The University of Chicago, Chicago, Illinois, United States
🇮🇳Jaslok Hospital and Research Centre, Mumbai, Maharashtra, India
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.